Xlife Sciences AG / Key word(s): Letter of Intent/PartnershipXlife Sciences AG paves the way for the next successful out-licensing and announces cooperation with Quant Biomarkers AG for the development of advanced biomarkers for kidney diseases 20.12.2023 / 07:00 CET/CESTXlife Sciences AG (SIX: XLS) and Quant Biomar.
The unified data-driven Biomarkers Platform specializes in the aggregation and synthesis of validated biomarker technologies for the development of sophisticated analytical products for Precision Medicine, Practical Human Longevity, InsurTech and InvestTechBASEL, Switzerland (BUSINESS WIRE) Deep Knowledge Group an.
The unified data-driven Biomarkers Platform specializes in the aggregation and synthesis of validated biomarker technologies for the development of sophisticated analytical products for Precision Medicine